| Nov 20 |
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
|
| Nov 19 |
Wall Street Breakfast Podcast: Fate Therapeutics Rises On Lupus Drug Data
|
| Nov 18 |
Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results
|
| Nov 18 |
Fate stock rallies 37% on positive Phase 1 data for FT819, FT522
|
| Nov 18 |
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
|
| Nov 18 |
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
|
| Nov 15 |
Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
|
| Nov 14 |
Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 13 |
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
|
| Nov 12 |
Fate Therapeutics GAAP EPS of -$0.40 beats by $0.01, revenue of $3.07M beats by $1.63M
|
